NCT06295952

A Study of Pasireotide in People With Prolactinoma

Pasireotide Treatment for Patients With Prolactinomas Who Need Treatment Beyond Dopamine Agonist Therapy

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The researchers are doing this study to find out whether pasireotide is an effective treatment for people with prolactinoma who cannot receive dopamine agonist therapy. Another purpose of this study is to find out whether pasireotide is a safe treatment for people with prolactinoma.

Conditions

• Prolactin-Producing Pituitary Tumor

Interventions

Type	Name	Description
DRUG	Pasireotide	Pasireotide will be initiated at 40 mg IM one time dose and if tolerated dose will be increased to 60 mg IM every 4 weeks +/-7 days.
OTHER	SF-36 and HADS	Baseline assessment will be conducted within 30 days of starting treatment, week 12, 24 and week 28.

Timeline

• Start date: 2024-02-27
• Primary completion: 2027-02-01
• Completion: 2027-02-01
• First posted: 2024-03-06
• Last updated: 2026-03-04

Locations

7 sites across 1 country: United States

Regulatory

• FDA-regulated drug study